Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
No Thumbnail Available
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Endothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient.
Description
Keywords
Takotsubo (stress) cardiomyopathy, Afatinib, EGFR mutation, tyrosine kinase inhibition, NSCLC